



28th September, 2017

| | |
|--|--|
| <p>To, The Manager, Listing Department, National Stock Exchange of India Ltd. "Exchange Plaza", C-1, Block G, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051.</p> <p>Ref. : (i) Symbol – DCAL (ii) Series – BE</p> | <p>To, Department of Corporate Services Bombay Stock Exchange Ltd. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001.</p> <p>Ref.: Scrip Code No. : 540701</p> |
|--|--|

SUB.: Disclosure pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015: The Company's wholly owned subsidiary, Carbogen Amcis AG successfully passes US FDA Inspection of its Headquarters Site in Bubendorf, Switzerland

Dear Sir,


With reference to the captioned subject, we would like to inform that the Company's wholly owned subsidiary, Carbogen Amcis AG's manufacturing site in Bubendorf, Switzerland, has successfully completed a routine U.S. Food and Drug Administration (FDA) inspection. The inspection was concluded without any major or critical observations or Form 483's, thus confirming that no concerns were discovered during the inspection.

Kindly take this on your record & oblige.

Thanking you.

Yours faithfully,
For, Dishman Carbogen Amcis Limited


Shrima Dave
Company Secretary



Dishman Carbogen Amcis Limited

Regd. Off.: Bhadr-Raj Chambers, Swastik Cross Road, Navrangpura, Ahmedabad-380 009. (India)

Phone : +91 (0) 79 26443053 / 26445807 Fax : +91 (0) 79 26420198

E-mail : dcal@dishmangroup.com Website : www.dishmangroup.com

CIN No. : U74900GJ2007PLC051338